ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1457	National Cancer Institute	Html	en	Esophageal Cancer Prevention (PDQ®)–Patient Version	Expert-reviewed information summary about factors that may influence the risk of developing esophageal cancer and about research aimed at the prevention of this disease.	cancer treatment 0.286725 cancer prevention trials 0.390926 protective factors 0.401778 following PDQ summaries 0.346585 PDQ cancer information 0.534006 Clinical Trials section 0.298655 esophageal cancer prevention 0.457641 clinical trials 0.60082 kidney damage 0.286456 cancer information summary 0.441092 lower esophagus 0.410035 lower sphincter muscle 0.357661 breast cancer prevention 0.318294 patients 0.3021 cancer patients 0.287439 latest published information 0.293022 cancer risk factor 0.360882 NCI’s PDQ 0.303811 NCI PDQ cancer 0.377375 stomach acid 0.297556 radiofrequency ablation 0.407628 PDQ Screening 0.291859 abnormal cells 0.372908 cancer risk factors 0.361881	Cancer prevention 0.541167 esophageal cancer 0.615396 cancer protective factor 0.339428 esophageal cancer increases 0.350762 Barrett esophagus 0.51844 Cancer Information Service 0.327169 prevention clinical trials 0.346293 Prevention Editorial Board 0.348856 treatment clinical trials 0.298225 National Cancer Institute 0.429589 Nonsteroidal anti-inflammatory drugs 0.365737 PDQ documents 0.293539 new treatment 0.29433 Cancer Care page 0.315656 PDQ database 0.297589 adenocarcinoma 0.336667 PDQ summary 0.318797 cancer clinical trials 0.340291 risk factors 0.504317 cancer information summaries 0.334653 comprehensive cancer information 0.334858 cancer 0.918802 esophagus produce 0.402126 esophagus 0.723728	CLICK HERE
1477	National Cancer Institute	Html	en	Bladder Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of bladder cancer.	Ta T1 bladder 0.556554 T1 high-grade bladder 0.506904 superficial bladder tumour 0.53364 bacillus calmette-guerin 0.516715 transitional cell carcinoma 0.695076 T1 transitional cell 0.496806 bladder cancer 0.986423 der Meijden AP 0.500317 clinical trials 0.520234 intravesical bacillus Calmette-Guerin 0.513656 primary superficial bladder 0.615094 non-muscle invasive bladder 0.495804 T1 bladder cancer 0.609466 Malignant bladder tumors 0.513021 superficial bladder cancer 0.787159 bladder tumors 0.61916 van der Meijden 0.529014 patients 0.562152 advanced bladder cancer 0.510311 Invasive T1 bladder 0.497584 high-grade T1 bladder 0.499638 newly diagnosed bladder 0.507837 superficial bladder tumors 0.5725 bacillus calmette-guerin therapy 0.514624	metastatic bladder cancer 0.563646 Canadian Bladder Cancer 0.508472 et al. 0.600299 bladder carcinogenesis 0.499935 high-grade bladder cancer 0.517381 bladder cancer. 0.49995 Eur Urol 0.553395 PUBMED Abstract 0.561063 invasive bladder cancer 0.614868 radical cystectomy 0.523916 non-muscle-invasive bladder cancer 0.573969 transurethral resection 0.509808 bladder cancer coincides 0.50967 advanced bladder carcinoma 0.508345 Abstract 0.681067 Herr HW 0.527009 Clin Oncol 0.566437 bladder carcinoma 0.546923 Urol 0.572506 urothelial carcinoma 0.574639 invasive bladder carcinoma 0.507022 nonmuscle-invasive bladder cancer 0.533359 Low-grade bladder cancers 0.509091 bladder cancer health 0.52478	CLICK HERE
1537	National Cancer Institute	Html	en	Newcastle Disease Virus (PDQ®)–Health Professional Version	Expert-reviewed information summary about the use of Newcastle disease virus (NDV) as a treatment for people with cancer.	metastatic tumor cells 0.405592 tumor cell lines 0.391976 human cancer cells 0.50054 genetically engineered NDV 0.389911 NDV oncolysates 0.413317 autologous tumor vaccine 0.41773 infected cells 0.416882 historical control subjects 0.398257 irradiated ESb cells 0.39152 Cancer Res 0.395898 disease virus therapy 0.398313 virus-modified tumor cells 0.412589 virus-modified autologous tumor 0.394368 autologous tumor cell 0.439505 patients 0.465722 Natl Cancer Inst 0.401926 human tumor cells 0.440276 lytic strains 0.409693 normal human cells 0.424643 cell vaccines 0.393769 et al. 0.391296 autologous tumor cells 0.542424 colorectal cancer patients 0.390231 cancer cells 0.51627 newcastle disease virus 0.925041	primary tumor cells 0.39623 PUBMED Abstract 0.426283 disease virus vaccine 0.404352 uninfected cancer cells 0.394475 tumor cells 0.60365 tumor cell vaccine 0.404276 progeny virus particles 0.393227 NDV 0.533791 Abstract 0.460011 human immune cells 0.389104 autologous cells 0.393227 NDV genetic material 0.390979 nonlytic NDV strains 0.407173 NDV-infected cancer cells 0.395154 malignant melanoma patients 0.394264 Human tumor cell 0.388361 renal cell carcinoma 0.423539 cells 0.622446 main NDV proteins 0.390649 ESb cells 0.400925 NDV strains 0.410203 regional lymph nodes 0.425639 cancer 0.567906 irradiated tumor cells 0.398885	CLICK HERE
1604	National Cancer Institute	Html	en	Bladder and Other Urothelial Cancers Screening (PDQ®)–Patient Version	Expert-reviewed information summary about tests used to detect or screen for bladder cancer.	red blood cells 0.494369 cancer treatment 0.489394 bladder cancers 0.541229 urine 0.494083 ongoing clinical trials 0.492966 bladder urothelium 0.575205 following PDQ summaries 0.556519 Transitional cell carcinoma 0.483769 PDQ cancer information 0.750577 cancer increases 0.491939 false-negative test result 0.489029 bladder cancer 0.812624 clinical trials 0.684635 test result 0.523443 special test strip 0.489962 cancer information summary 0.626401 clinical trial 0.502183 breast cancer prevention 0.514992 false-positive test result 0.488801 cancer patients 0.484495 latest published information 0.497666 NCI’s PDQ 0.51339 cancer symptoms 0.50531 NCI PDQ cancer 0.589485	tests 0.518118 Squamous cell carcinoma 0.486084 PDQ Screening 0.538371 screening tests 0.491835 Cancer Information Service 0.53331 urothelial cancers 0.536876 PDQ Bladder 0.571685 Prevention Editorial Board 0.549647 treatment clinical trials 0.491831 National Cancer Institute 0.634201 PDQ documents 0.50321 cell carcinoma 0.486793 new treatment 0.498073 Cancer screening trials 0.570719 Cancer Care page 0.519283 PDQ database 0.508182 risk factor 0.512484 PDQ summary 0.54439 cells 0.496479 cancer information summaries 0.541898 comprehensive cancer information 0.541535 renal pelvis 0.488981 cancer 0.961972 Urothelial Cancers Screening 0.519534	CLICK HERE
1723	National Cancer Institute	Html	en	Cell Phones and Cancer Risk	A fact sheet that outlines the available evidence regarding use of cellular/mobile telephones and cancer risk.	study participants 0.44259 Self-reported cell phone 0.407518 past cell phone 0.400866 cell phone calls 0.471967 interphone study 0.417191 cell phone subscribers 0.456865 brain glucose metabolism 0.405692 brain tumors 0.529155 case-control study 0.507596 typical cell phone 0.408953 radiofrequency electromagnetic radiation 0.493663 radiofrequency energy exposure 0.501417 cell phone service 0.411175 radiofrequency energy 0.823507 brain cancer 0.549627 cell phone exposure 0.408273 mobile phone radiation 0.402738 cell phone base 0.419397 mobile phone 0.45428 specific absorption rate 0.399693 GSM mobile phone 0.393442 glucose metabolism 0.4091 Brain cancer incidence 0.408493 brain tumor incidence 0.393633 cell phone user 0.438311	study 0.591826 cohort study 0.434065 United States 0.44975 epidemiologic studies 0.488267 brain tumor risk 0.390841 cell phone 0.960278 cell phone technology 0.436997 National Cancer Institute 0.439672 long-term cell phone 0.404741 cell phones 0.77677 international case-control study 0.404344 prospective cohort study 0.39373 brain tumor 0.434845 brain cancer risk 0.419878 brain 0.559028 regular cell phone 0.406823 non-ionizing radiation 0.395758 cell phone radiofrequency 0.472899 cell phone users 0.536299 cell phone records 0.414439 et al 0.586681 cancer risk 0.424868 cancer 0.54982 risk 0.454009	CLICK HERE
1903	National Cancer Institute	Html	es	Tratamiento del linfoma no Hodgkin infantil (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del linfoma no Hodgkin infantil.	siguientes procedimientos 0.533869 posibles efectos tardíos 0.429839 células madre 0.925937 posibles factores 0.42224 adultos jóvenes 0.471015 estadio iv 0.456127 Burkitt recién 0.429453 sistema linfático.Para 0.433317 faja ajustadora 0.424807 gen alk 0.453637 leucemia linfoblástica aguda 0.499911 estadio ii 0.457571 siguientes especialistas 0.421884 siguientes tipos 0.435023 rayos x 0.42189 después.ampliar ecografía 0.422758 enlace drugs approved 0.552427 niño ayuda 0.422955 Sudores nocturnos 0.425131 ondas sonoras 0.421599 células t 0.997508 efectos tardíos 0.61792 PDQ Efectos tardíos 0.432774 líquido cefalorraquídeo 0.752047	sección linfoma 0.486518 Linfoma folicular tipo 0.701733 linfocitos b 0.461134 La terapia 0.636115 encontrarlo.ampliar exploración 0.423664 determinados cambios 0.538253 PDQ Tratamiento 0.508964 líquido incoloro 0.436562 explorador tep 0.424899 siguientes factores 0.424861 sistema nervioso central 0.543338 proteína llamada cinasa 0.449366 mayores probabilidades 0.423685 Non-Hodgkin Lymphoma 0.486305 estadio i 0.458742 tipo paniculitis 0.446711 Estados Unidos 0.425103 estadio iii 0.456847 tejido linfoide 0.449965 ósea fabrica glóbulos 0.477114 almacena glóbulos 0.436048 células b 0.553761 Hodgkin infantil recidivante 0.525837	CLICK HERE
1922	National Cancer Institute	Html	es	Tratamiento del cáncer de próstata (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del cáncer de próstata.	paciente presente síntomas 0.437409 siguientes procedimientos 0.452293 dé tratamiento 0.439746 estadio iv 0.493208 hiperplasia prostática benigna 0.97293 ecografía transrectal 0.704162 pequeña cantidad 0.628387 peores efectos 0.412864 estadio ii 0.558135 siguientes tipos 0.419876 tumor dosis 0.421814 rayos x 0.418531 sistema urinario masculino 0.436824 ondas sonoras 0.422219 principal fuente 0.412408 características sexuales masculinas 0.423477 enlace medicamentos 0.465713 National Cancer Institute 0.412027 sustancia radiactiva llamada 0.426571 biopsia.ampliar ecografía 0.431707 Instituto Nacional 0.421293 estadios iia 0.418459	hormonas masculinas 0.458793 PDQ Tratamiento 0.424516 hormonas sexuales masculinas 0.442195 estadio iia 0.431816 siguientes problemas 0.426176 presente sección 0.409743 tejidos cercanos.A veces 0.421604 Physician Data Query 0.443132 posibles problemas 0.411863 Estados Unidos 0.4216 estadio iii 0.498677 linfadenectomía pélvica 0.487486 prostatectomía radical.ampliar resección 0.439705 aparato reproductor masculino 0.440962 siguientes sustancias 0.416831 hipertrofia prostática benigna 0.438255 alta intensidad 0.548873 prostatectomía retropúbica 0.464416 Ganas repentinas 0.423669 próstata solas 0.515159 siguientes pruebas 0.46951 siguientes estadios 0.460134	CLICK HERE
2021	National Cancer Institute	Html	es	Prevención del cáncer de cuello uterino (PDQ®)–Versión para pacientes	Información revisada por expertos sobre los factores que pueden aumentar el riesgo de cáncer de cuello uterino y los enfoques que podrían ayudar a la prevención de esta enfermedad.	Visuals Online 0.544747 PDQ Exámenes 0.729141 Internet NCI 0.599334 siguientes factores 0.942852 voluntarios sanos 0.571782 Physician Data Query 0.821847 Estados Unidos 0.732136 suficiente ejercicio 0.608117	prevención revisa 0.577919 PDQ Prevención 0.648162 cuánto tiempo 0.58363 National Cancer Institute 0.579131 invasivo aumenta 0.607513 siguientes riesgos 0.566231 siguientes sumarios 0.745167 Instituto Nacional 0.648132	CLICK HERE
2050	National Cancer Institute	Html	es	Análisis del antígeno prostático específico (PSA)	Hoja informativa sobre la prueba del antígeno prostático específico (PSA) y los exámenes selectivos de detección para el cáncer de próstata, y clarifica los beneficios y limitaciones de dicha prueba.	posibles complicaciones 0.529476 United States Preventive 0.549836 hiperplasia prostática benigna 0.569875 fusión génica tmprss2-erg 0.5485 estudio plco 0.535774 PLCO trials 0.538088 eréctil o incontinencia 0.532144 médico quizás 0.54755 ng per milliliter 0.54786 concentration-based assay 0.526257 Pauler DK 0.526835 structure-based isopsa assay 0.54715 estudio clínico plco 0.561758 tanta lentitud 0.531594 posibles perjuicios 0.59922 riesgos y beneficios 0.531533 Servicios Preventivos 0.526931 European Randomised Study 0.54659 hiperplasia benigna 0.602949 Preventive Health Services 0.541802 llamadas isoformas 0.529743 Screening Draft Recommendations 0.555159	Hugosson J 0.571924 espectro de  isoformas 0.553214 Instituto Nacional 0.525806 próstata en asociación 0.528933 PSA quizás 0.924082 posibles efectos 0.527227 Internal Medicine 0.527548 Services Task Force 0.63375 among men with 0.545229 estados benignos 0.530298 agrandamiento benigno 0.537792 PubMed Abstract 0.784346 prostate cancer 0.975142 estadio inicial quizás 0.562336 obstante exámenes 0.563732 New England Journal 0.630867 Goodman PJ 0.525307 de 1 muerte 0.528041 Roobol MJ 0.576631 pequeños tumores 0.530536 Heijnsdijk EAM 0.527351 Hafron JM 0.526062	CLICK HERE
16652	National Cancer Institute	Html	en	Track 2: Oncology Product Research and Review for B.C. Oncologists	NCI and FDA collaborate to train physicians in aspects of drug, biologic, or device development and standards for assessing medical product safety. Learn more about this cancer training program.	regulatory research 0.59502 pre-screened pool 0.579358 related issues 0.586202 reviewer training 0.576269 FDA scientific review 0.753981 later potential exposure 0.734497 regulatory meetings 0.582894 permanent residency 0.578922 Medical Center Dr 0.681374 fellows 0.986099 application guidelines 0.556272 clinical trials 0.592135 translational research 0.577443 various courses 0.556327 grand rounds 0.56318 various regulatory activities 0.729982 Regulatory Review Fellowships 0.720449 Cancer Training 0.567352 branch chief 0.561743 clinical divisions 0.572535 FDA Centers 0.764003 Review list 0.568699 training program 0.574879 application materials 0.560557 relevant federal statutes 0.739941	formal training 0.600328 U.S. citizenship 0.583794 earliest start date 0.680448 particular product 0.577316 office meetings 0.559685 senior member 0.553306 regulatory presentations 0.582975 guidance document development 0.691126 designee 0.446918 basic bench science 0.743323 principal investigators 0.569533 medical product safety 0.755593 Office Phone 0.552001 NCI-FDA Research 0.556736 one-year program 0.583619 supplemental training 0.588935 division director 0.57667 efficacy 0.476236 limited human exposure 0.741021 FDA medical review 0.830025 device development 0.579671 broader patient population 0.734715 clinical reviews 0.569332 pharmacology/toxicology 0.443629	CLICK HERE